Efficacy of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults living in a TB endemic region
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2018
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 19 Feb 2018 According to an Aeras media release, data regarding Learnings associated with the impact of implementing an effective community engagement strategy on retention rates in this study will be presented at the Global Forum on TB Vaccines 2018.
- 12 Jan 2018 Planned End Date changed from 22 Oct 2018 to 25 Nov 2018.
- 12 Jan 2018 Planned primary completion date changed from 22 Oct 2018 to 25 Nov 2018.